2025
Perspectives, Viewpoints, and Editorials
- F.D.A. Nominee to Face Grilling Over Cutbacks and Policy Shifts-New York Times (3/06/25)
- Weight loss drugs may become harder to get. What does that mean for patients?-wbur (2/28/25)
- ANALYSIS: RFK Jr.’s health revolution: reform or risk?-Yale Daily (2/28/25)
- On measles outbreak, the Trump administration’s messaging strikes some as off-key-STAT News (2/27/25)
- RFK Jr. readies review of childhood vaccine schedule after pledging not to-Endpoints News (2/19/25)
- Study Finds Websites Aren’t Always Transparent About Compounded GLP-1 RAs-Medscape (published 2/13/25)
- Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries (2/01/25)
- Integrating Equity Into Licensing Agreements For Taxpayer-Funded Technologies (12/19/25)
- Technology transfer, intellectual property, and the fight for the soul of WHO (12/05/25)
- RFK Jr. says he's not anti-vaccine in Senate confirmation hearing-KCBS Radio (1/29/25)
- ‘Incredibly irresponsible’: Hims Super Bowl ad downplays risks of compounded drugs-STAT News (1/28/25)
- What will happen to Medicare drug pricing negotiations under Trump?- MM+M (1/24/25)
- Advocates Slam US-Gilead Patent Settlement Over HIV PrEP Drugs-Bloomberg Law News (1/21/25)
- Misleading Statements Common in Online Ads for Compounded GLP-1s tctMD (1/20/25)
- Online marketing for compounded GLP-1 drugs overstates benefits and underplays risks-STAT News (1/17/25)
- E-sellers of compounded weight-loss drugs fail to reveal risks, research shows-Reuters (1/17/25)
- Despite New FDA Guidance, Doctors Say Accelerated Approval Process Still Flawed-MedCentral (1/16/25)
- Federal watchdog raises some concerns about the FDA’s accelerated approval program-STAT News (1/14/25)
Op-Eds
- Ten‐Year Medicare Use and Spending on the 10 Drugs Selected for Negotiation Under the Inflation Reduction Act | Journal of the American Heart Association (1/23/25)
- Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists (1/17/25)
- Assessing Medicare’s Coverage With Evidence Development Program (1/06/25)
Public Comments
- Comment on “Expedited Program for Serious Conditions – Accelerated Approval of Drugs and Biologics” Draft Guidance, Docket No. FDA-2024-D-2033 (3/07/25)
- Comment on “Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway” Draft Guidance, Docket No. FDA-2024-D-3334 (3/11/25)